![]() The reviewers will have this information available during their evaluation.Ībstracts of Trials in Progress (TiP), i.e., descriptions of trials that have not reached the primary endpoint and do not include any clinical data, are eligible for submission to the ASH Annual Meeting. If your abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of your study. Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid.The reviewers will have this information available during their evaluation. In this case, please use the Updated Analyses section of the abstract form to explain the extent and the significance of the new data. Data from the long-term follow-up of previously presented or published clinical trials may be submitted only if they include significant new information.All studies reported in submitted abstracts involving human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.The only exceptions are Trials in Progress abstracts (see below for information on criteria for a Trial in Progress abstract). An abstract must include primary scientific, clinical, meta-analytic, health outcomes or epidemiologic data.If the original designated presenting author cannot attend, a co-author may be designated as an alternative presenter. Unless announced otherwise by ASH, presenting authors of abstracts accepted for oral presentation or poster presentation must attend the 2023 Annual Meeting in person in San Diego.Forwarding all correspondence to all co-authors, including ASH policies and guidelines relating to disclosure of financial relationships.Obtaining all of the conflict-of-interest disclosure and copyright transfer information from co-authors.Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.Failure to get approval from all authors will result in rejection of the abstract. Ensuring that all authors have read the abstract and agreed to be co-authors.The presenting author is responsible for the following:.The presenting author must be one of the co-authors listed on the submitted abstract.The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Contact Information” section of the online abstract submission system. ![]() Responsibilities of the Presenting Author All relevant conflicts of interest must be disclosed, and data presented fairly and transparently. ![]() Therefore, presenting authors are no longer subject to ACCME restrictions, and can be employees of publicly-traded or privately-held healthcare companies or owners of privately-held entities. In contrast to past years, oral abstract and poster presentations will no longer be contained within the ACCME-accredited portion of the annual meeting.The content of the abstract must fit into one of the ASH 2023 categories.ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of each abstract that they sponsor. If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member.At least one of the authors must be a current ASH member with up-to-date payment of membership dues.To submit an abstract, the following criteria must be met: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |